TERN-701 for Certain Patients with Chronic Myeloid Leukemia... "This is an exciting time for everyone involved in the TERN-701 program ... TERN-701 BTD is based on data from the ongoing Phase 1/2 ...
) Today's turnover on SASE. 14.701,50 KM 23.4.2026 14.43.53 On today's trading session on SASE the overall turnover amounted to 14.701,50 KM ... 23-04-26_1.xlsx;205581 ; On today's trading session on SASE the overall turnover amounted to 14.701,50 KM.
FDA feedback enables Corbus to proceed with proposed registrational study design and endpoints to support potential accelerated approval in second-line HNSCC and cervical cancer ... .
). /KASE, March 26, 2026/ - By shares trading results on Kazakhstan Stock Exchange (KASE) on March 26, 2026, KASE Index decreased by 71.70 points (0.92%) from 7,773.44 to 7,701.74. The first deal fixed the index at 7,833.56 ... KASE Index change ... (noodl.
Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR..ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with CML... .
Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR..ABL1 tyrosine kinase inhibitor currently in Phase 1/2 development for certain patients with CML... .